9F1 — Diagonal Bio AB Cashflow Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- €0.78m
- -€1.96m
- SEK0.06m
Annual cashflow statement for Diagonal Bio AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 41 W | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.583 | -11.7 | -16.2 | -11.7 | -9.42 |
| Depreciation | |||||
| Non-Cash Items | — | — | — | 0 | — |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.753 | 0.72 | 0.391 | 6.45 | -5.36 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 0.17 | -10.9 | -15.8 | -5.23 | -13.8 |
| Capital Expenditures | -5.98 | -8.59 | -4.96 | -4.25 | -1.67 |
| Purchase / Acquisition of Intangibles | |||||
| Cash from Investing Activities | -5.98 | -8.59 | -4.96 | -4.25 | -1.67 |
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.48 | 36.6 | 13.5 | -1.14 | 13.3 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.67 | 17.1 | -7.18 | -10.6 | -2.15 |